An oil processing facility at Abqaiq and the nearby Khurais oil field was attacked on Saturday.Marketsread more
"There is reason to believe that we know the culprit," Trump said in a post on Twitter.Politicsread more
Brent crude surged by as much as 19.5% to reach $71.95 per barrel on Monday, the biggest intra-day jump since the Gulf War in 1991.Oilread more
The strike, depending on its length, could easily cost GM hundreds of millions of dollars. The last time the union declared a strike at GM was in 2007.Autosread more
Saudi Aramco has 35-40 days of supply to meet contractual obligations, a source close to the matter told CNBC.Energyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy protection on Sunday.Health and Scienceread more
Saudi Arabia on Saturday shut down half its oil production after a series of drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's...Futures & Commoditiesread more
U.S. stock futures sank amid fears that a surge in oil prices following an attack in Saudi Arabia could slow down global economic growth.Marketsread more
The recommendations include changing corporate reporting structures, creating a new safety group, and changing the cockpits of future planes to accommodate new pilots with...Aerospace & Defenseread more
The state would become the second in the country, behind Michigan, to ban the sale of fruit flavored e-cigarettes, which are popular with teenagers.Health and Scienceread more
Shares of Sage Therapeutics climbed 15 percent Tuesday after the company said the Food and Drug Administration has cleared it to expedite development of its drug to treat major depressive disorder and postpartum depression.
Sage said its ongoing trial in women with postpartum depression will now be designated a pivotal trial, which allows the data, if positive, to support a regulatory filing. The company plans to start a phase 3 trial in major depressive disorder in the second half of this year.
The drug, SAGE-217, in February received breakthrough therapy designation, which allows for a potentially expedited regulatory approval process. This came after Sage announced breakthrough results from a phase 2 trial in December.
Commissioner Scott Gottlieb has pushed the FDA to review and approve drugs faster. Last year, Gottlieb's first leading the agency, the FDA approved a record number of generic drugs and a handful of biosimilars, or copycat versions of complex, biologic drugs.
"Sage is excited to receive feedback from the FDA that provides a possible groundbreaking path forward for the development of SAGE-217 for the treatment of depression," said CEO Dr. Jeff Jonas.
Before the start of trading Tuesday, shares of Sage had slipped nearly 11 percent this year.